Murex Licenses Ariadne's Pathway Studio for Cancer Drug Development | GenomeWeb
NEW YORK (GenomeWeb News) – Murex Pharmaceuticals licensed from Ariadne Genomics its Pathway Studio software to help develop cancer therapeutics, Ariadne said yesterday.
Murex will use Pathway Studio to develop computer-based models to identify and validate cancer targets.

Financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.